Human leukocyte antigen-G (HLA-G) expression is modulated by immunosuppressant use and is associated with lower incidence of graft rejection and cardiac allograft vasculopathy (CAV). We examined whether everolimus induces HLA-G expression and inhibits human coronary artery smooth muscle cell (HCASMC) proliferation, a critical event in CAV. Also, we examined whether TNFα-stimulated neutrophil adhesion is inhibited by HLA-G on human coronary artery endothelial cells (HCAECs).
HLA-G expression in HCASMCs following everolimus treatment was determined by
western-blot densitometric analysis. HCASMCs proliferation following incubation with recombinant HLA-G was determined by automated cell counter detecting 2-10 µm particles. Assessment of recombinant HLA-G on neutrophil adhesion to HCAECs in response to TNF-α induced-injury was determined by nonstatic adhesion assays. HLA-G expression was upregulated in HCASMCs following everolimus exposure (1000 ng/ml; P < .05). HLA-G (500, 1000 ng/ml; both P < .05) reduced HCASMC proliferation and inhibited TNFα-stimulated neutrophil adhesion to endothelial cells at all concentrations (0.1-1 ng/ml; all P < .001). Our study reveals novel regulation of HLA-G by everolimus, by demonstrating HLA-G upregulation and subsequent inhibition of HCASMC proliferation. HLA-G is a potent inhibitor of neutrophil adhesion to HCAECs. Findings support HLA-G's importance and potential use in heart transplantation for preventative therapy or as a marker to identify patients at high risk for developing CAV.
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| INTRODUC TI ON
Cardiac allograft vasculopathy (CAV) is a predominant cause of morbidity and mortality in cardiac transplantation patients.
1 Histologic profiling reveals CAV is a major diagnostic and therapeutic challenge with onset as early as one year posttransplant. [2] [3] [4] As CAV constitutes a major limitation to long-term survival posttransplant, a substantial area of research focuses on detecting ways of inhibiting cellular processes that contribute to its formation. Our group has focused on a molecule with immunosuppressive properties, human leukocyte antigen-G (HLA-G).
HLA-G belongs to major histocompatibility complex class I molecules; however, its function differs from other molecules in this category. HLA-G induces immunosuppression rather than immune activation. 5 Initially studied in pregnancy, HLA-G was found to facilitate a tolerogenic environment for the allogeneic fetus by protecting it from the maternal immune system by exerting a series of inhibitory functions, which alters immune cells' allorecognition and attack. [6] [7] [8] Because of its powerful role as a tolerogenic molecule, HLA-G has been studied in transplantation. 9 Expression of HLA-G in tissues, serum, and plasma samples of heart, liver, lung, and kidney transplant recipients has been associated with decreased graft rejection.
10-12
Although regulation of HLA-G remains to be elucidated during the pre-and posttransplant periods, it appears that immunosuppressive therapy plays some role in its regulation. Serum HLA-G was detected significantly in more patients receiving everolimus than in patients receiving mycophenolate mofetil (MMF) (78% vs 25%, respectively). 13 Everolimus, a potent human coronary artery smooth muscle cell (HCASMC) proliferation signal inhibitor, is known to reduce CAV development posttransplant. 14 HLA-G expression has been previously associated with decreased CAV incidence after heart transplantation. 15 Vascular smooth muscle cells (SMC) have a pivotal role in CAV development, as they are the main generators of vascular compromise. According to previous studies, HLA-G molecules affect endothelial cell activity. HLA-G was found to inhibit human umbilical vein endothelial cell proliferation, migration, and capillary tubule formation. 16 As HCASMCs have an important role in CAV development, we aimed to determine whether HLA-G can be upregulated in this cell type.
The study objectives were (1) Inc, San Diego, CA, 5% fetal bovine serum). Cells used for these experiments were passaged two to four times.
| ME THODS
Cells being cultured were placed in 10 cm dishes with 10 ml culture medium, for 24 hours to permit cell attachment. Once grown to full confluence, medium was discarded and cells were washed with 10 ml of warm phosphate buffer saline. Cells were detached by adding 2 ml 0.25% trypsin solution with EDTA (Life Technologies, Grand
Island, NY) and incubated for 2 minutes at room temperature. Four milliliters of the medium were then added to culture dishes to block trypsin enzymatic activity. Cells were resuspended by repeated pipetting and transferred into new culture dishes. Medium was then added to achieve full desired volume of 10 ml. Cells were incubated for 48 hours to allow adequate attachment time. Culture medium was then replaced to prevent contamination and allow experimental cells to grow to full confluence. This cell culture method was used for all experiments.
| Treatment of HCASMCs with everolimus
Cells were subjected to everolimus for 24 hours, ranging from 0.1 to 1000 ng/ml. The vehicle for treatment was Dimethyl Sulfoxide.
Control cells were treated with vehicle alone. Following treatment, cultures were assessed for HLA-G expression by western immunoblotting.
| Western immunoblotting
Twenty micrograms of protein samples was loaded and separated using 10% running and 4% stacking TRIS-glycine SDS-PAGE gels. Comparisons between groups were made using computerized densitometric analysis with a commercially available software program (GS800 Calibrated Densitometer and Quantity One 1D-Analysis Software, Bio-Rad, Mississauga, Ontario).
| Treatment of HCASMCs with HLA-G and assessment of proliferation
HCASMCs were subjected to recombinant HLA-G (OriGene Technologies, Rockville, MD) (100, 500, 1000 ng/ml) for 24, 48, and 120 hours. These concentrations were chosen to assess HLA-G's effects at a wide series of doses. The vehicle for treatments was the HLA-G buffer (10% Glycerol, 100 mM Glycine, were assessed for SMC proliferation in a nonblinded fashion, using an automated cell counter set to detect particles of 2-10 µm in diameter.
| Neutrophil isolation
Neutrophils were isolated from peripheral blood of healthy volunteers as described before. 17 
| Treatment of HCAECs with HLA-G and TNF-α
We examined the effect of TNF-α on neutrophil adhesion with/ without HLA-G on HCAEC. Confluent HCAECs were exposed to purified recombinant HLA-G (1000 ng/ml) for 48 hours. This concentration was chosen based on previous results, where SMC proliferation was inhibited following exposure to 1000 ng/ml of HLA-G.
The vehicle for treatment in the current study was the HLA-G buffer.
Control cells were treated with vehicle alone. Experimental cells were exposed to various doses of TNF-α (0.1-1 ng/ml) for 4 hours with or without the presence of HLA-G. A nonstatic adhesion assay was performed as follows.
| Neutrophil adhesion
Neutrophil adhesion to HCAEC cultures subjected to TNF-α treatment with/without HLA-G was assessed with a nonstatic adhesion assay as described previously. 
| Statistical analysis
Parametric statistical comparisons of all pairwise values were performed using one-way analysis of variance (ANOVA) to evaluate the association of everolimus and HLA-G expression. We used two-way ANOVA to study the effect of HLA-G on SMC proliferation, using Student-Newman-Keuls post-hoc test. We used one-way ANOVA using Dunnett's method to evaluate the effect of HLA-G and neutrophil adhesion. The SigmaPlot program (v11.0.0.77; Systat Software Inc, San Jose, CA) was used for statistical analyses. A value of P < .05 was required for statistical significance.
| RE SULTS

| Everolimus upregulates HLA-G in HCASMCs
HCASMC cultures expressed HLA-G at baseline (0.27 ± 0.06).
Expression of HLA-G was detected at increasing amounts in a dosedependent fashion following everolimus treatment ( Figure 1A ). At 0.1 ng/ml of everolimus the HLA-G:β-actin ratio was 0.22 ± 0.04, at 10 ng/ml the ratio was 0.33 ± 0.06, at 100 ng/ml the ratio was 0.35 ± 0.03, and at 1000 ng/ml the ratio was 0.54 ± 0.06. Total protein expression increased significantly in response to everolimus treatment at 1000 ng/ml (P < .014) compared to control, as detected by western immunoblotting. β-actin was used as loading control and there were no differences between groups. Protein content is expressed as the HLA-G:β-actin ratio ( Figure 1B ).
| HLA-G inhibits HCASMC proliferation
HCASMCs in the control group proliferated as expected, and their cell count (#cells/ml) was 0.60 ± 0.08 × 10 5 at 24 hours, 1.3 ± 0.04 × 10 5 at 48 hours, and 4.59 ± 0.29 × 10 5 at 120 hours ( Figure 2 ). There was a significant increase in proliferation at all -time points (P < .001). At 24-and 48 hour treatment there was no significant difference in proliferation between all concentration groups (100, 500, and 1000 ng/ml). At 120 hours posttreatment, proliferation of cells treated with HLA-G at 500 and 1000 ng/ml was significantly lower (*P = .041 and *P = .004, respectively) than that of the control group. At 120 hours there was also a significant decrease in proliferation of cells treated with 1000 ng/ml when compared to the 100 ng/ml group (*P = .020). Cell viability was similar across all time points (98%-99%).
| HLA-G inhibits neutrophil adhesion to HCAEC
Incubation with HLA-G at 1000 ng/ml alone had no significant effect on neutrophil adhesion compared to control (4.84 ± 0.25 vs.
3.73 ± 0.22, P > .05, respectively). As expected, exposure of EC to four hours of treatment with TNF-α at concentrations of 0.1, 0.5, and 1 ng/ml increased neutrophil adhesion to 9.98 ± 0.31, 26.97 ± 0.50, and 31.98 ± 0.51, respectively (*P < .001), compared to control 3.73 ± 0.22 ( Figure 3A) . Incubation of EC with HLA-G + TNF-α, significantly abrogated TNF-α-stimulated neutrophil adhesion.
Adhesion decreased from 9.98% to 7.36% ± 0.45% (#P < .001) at 0.1 ng/ml of TNF-α, from 26.97% to 24.20% ± 0.83% (#P < .001) at 0.5 ng/ml TNF-α, and from 31.98% to 29.41% ± 0.91% (#P = .005) at 1 ng/ml TNF-α ( Figure 3B ).
F I G U R E 2
Assessment of SMC proliferation inhibition in response to soluble HLA-G treatment. There was a significant increase in proliferation over time (by two-way ANOVA, time effect F = 954, #P < .001). HLA-G demonstrated an inhibitory effect (HLA-G effect F = 3, *P = .03). There was no interaction between time and HLA-G exposure (time and HLA-G effect F = 1.35, P = .2). Student-Newman-Keuls multiple comparison method specified a decrease in proliferation of cells treated with 1000 ng/ml of HLA-G when compared to control and with 100 ng/ml dose (*P < .05), and also a difference between groups treated with 500 ng/ml and control (*P < .05). Means ± SEM, n = 8 F I G U R E 3 Assessment of HLA-G on neutrophil adhesion to human coronary artery EC injured by cytokines. (A) The dose dependent effect of neutrophil adhesion upon EC injury by TNF-α exposure (0.01, 0.1, 0.5, 1, and 10 ng/ml). *P < .05 vs control group. Means ± SEM, n = 4. (B) The effect of HLA-G on neutrophil adhesion in response to TNF-α induced EC injury. Increased neutrophil adhesion observed with higher TNF-α concentrations (by two-way ANOVA, TNF-α effect F = 687, *P < .001). The addition of 1000 ng/ml of HLA-G significantly reduced neutrophil adhesion (HLA-G effect F = 27, #P < .001). There was no interaction between TNF-α and HLA-G exposure (TNF and HLA-G effect F = 0.01, P = .9). Student-Newman-Keuls multiple comparison method specified significant differences between HLA-G and non-HLA-G treated groups at all TNF-α concentrations (0.1, 0.5, 1, and 10 ng/ml), respectively (P < .001, P < .001, P = .005). Means ± SEM, n = 8
| D ISCUSS I ON
| Everolimus induces HLA-G expression in HCASMCs
Our experiment demonstrates for the first time that everolimus significantly increases HLA-G expression in HCASMC. Previous studies report HLA-G was expressed in ECs of chorionic fetal vessels during embryonic development; however, as vessels matured, HLA-G was no longer expressed. 19, 20 Our previous investigations revealed that treatment with progesterone increases HLA-G in HCAECs, human aortic endothelial cells, and HCASMCs. 21 These findings were in accordance with other studies that found an upregulation of HLA-G in JEG-3 choriocarcinoma cells and first trimester trophoblasts.
22
Previous investigations in our laboratory compared serum HLA-G expression in heart transplant patients treated with two different immunosuppressants, everolimus and MMF. We found that patients treated with everolimus had higher HLA-G levels. 13 These results support the rationale for using everolimus in our current ex- The relevance of our findings needs to be studied in vivo. The recommended everolimus therapeutic range is 3-8 ng/mL in transplant patients. 18 In our in vitro studies, the dose that had inhibitory effects on SMCs was 1000 ng/ml. Everolimus at 10 ng/ml, the closest concentration to clinical practice, did not have significant effects in SMCs. Therefore, everolimus at therapeutic doses may not upregulate HLA-G in vivo.
| HLA-G inhibits HCASMC proliferation in vitro
Our experiments are the first to demonstrate HLA-G's ability to inhibit HCASMC proliferation. Interestingly, we found significantly higher inhibition of proliferation following treatment with a high HLA-G concentration, compared to control and the lowest HLA-G doses, suggesting that high HLA-G doses are needed to elicit an inhibitory effect (Figure 2 ).
Our findings suggest that prolonged exposure to HLA-G is needed to alter the proliferative ability of SMC. High HLA-G concentrations that had an inhibitory effect might not have significance in clinical practice as in our heart transplant population the maximum concentration of HLA-G detected in plasma is 214 ng/ml.
However, in future studies, exogenously administered HLA-G might prove to be an efficient way of enhancing its expression and maximizing its beneficial inhibitory effects.
The fact that HLA-G expression in biopsies and serum/plasma of transplant patients is associated with reduced episodes of rejection and CAV suggests that HLA-G might play a role within the coronary artery. 15, 24 A similar inverse association between HLA-G expression and graft failure has been reported in other solid organ transplants. 10, 11 However, no research examines the protective effect of HLA-G within the vasculature of these allografts.
| HLA-G inhibits neutrophil adhesion to HCAEC following cytokine injury
Results revealed decreased neutrophil adhesion in response to sHLA-G with varying concentrations of TNF-α ( Figure 3B ). Inhibition of neutrophil adhesion to the endothelium is of particular interest as this mechanism plays an important role in the initial phase of acute rejection, with subsequent repercussions on CAV formation.
As a link between acute rejection and CAV, it has been proposed that inflammatory responses and vascular cellular damage, following rejection episodes, cause endothelium injury, and initiate CAV formation. 25 The interaction of neutrophils with the endothelium plays an important role during the inflammatory process.
Exactly how HLA-G exerts this effect has not yet been determined. We propose that prolonged EC exposure to sHLA-G confers protection from cytokine-induced injury, or inhibits EC activation post injury, thereby inhibiting the release of proinflammatory cytokines that perpetuate the inflammatory response. Also, in response to endothelial damage and inflammatory molecules, the activated vascular endothelial layer expresses a series of cell adhesion molecules on its surface, such as ICAM-1, VCAM-1, and selectins. 26, 27 All these molecules interact with surveying neutrophils and facilitate rolling and adhesion to the endothelium. 27 Another potential mechanism of HLA-G is through inhibition of the expression of EC adhesion molecules. With less stimulation from factors that cause adhesion, fewer neutrophils adhere to vessel walls and transmigrate into tissues, decreasing the overall detrimental effects.
Another potential explanation for the effects seen is the fact that neutrophils express the ILT4 inhibitory receptor. 28 The ILT4
receptor, also expressed on monocytes, dendritic cells, and tumor cells, has shown to impair immune activation following interaction with HLA-G. Given this, the sHLA-G remnants, once EC culture medium is discarded, could bind the ILT4 receptor on neutrophils and exert inhibitory effects. This receptor has shown to have a stronger preference for binding HLA-G than any other MHC class I, when compared to the ILT2 receptor. 29 This suggests that neutrophils can indeed be the target of the inhibitory effects of HLA-G due to the presence of ILT4 on their surface.
Although the role of HLA-G as an adhesion inhibitor has not been extensively studied, a recent investigation revealed the ability of HLA-G to block human natural killer rolling adhesion on porcine EC. 30 This is of particular interest because the rolling adhesion of natural killer represents the main mechanism of their recruitment to the injury site where they adhere tightly and migrate through the endothelium causing cytotoxic effects.
A limitation of our neutrophil adhesion study was the absence of multiple HLA-G doses. The concentration of 1000 ng/ml was chosen based on the proliferation study, this concentration having a more profound effect on SMCs. Also, as TNF-α has strong cytolytic effects at low doses, we felt that lower concentrations of HLA-G would not overcome the effects of TNF-α. Even at 1000 ng/ml, HLA-G was able to only partially inhibit neutrophil adhesion.
In 
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